Thursday, March 10, 2011

Supreme Court denies cert. in "pay-to-delay" case

The U.S. Government's efforts to limit pharmaceutical manufacturers' actions to keep generic medications off the market for a specified time (through deals called "pay-to-delay") hit a brick wall.  The SCOTUS declined to review a decision by the Second Circuit denying a legal challenge regarding Bayer AG to pay a potential generic competitor, Teva Pharmaceutical's Barr Pharmaceuticals, in a 1997 deal to delay introduction of a generic version of Cipro, a popular antibiotic.  Click here for the Reuters' story.

No comments:

Post a Comment